Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - nirmatrelvir; ritonavir -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - nirmatrelvir; ritonavir -

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

emcure pharmaceuticals ltd. - atazanavir sulphate, ritonavir - tablets film-coated - 300mg+ 100mg

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - ritonavir 100mg - film coated tablet - 100 mg - active: ritonavir 100mg excipient: calcium hydrogen phosphate colloidal silicon dioxide copovidone opadry white 16b18449 sodium stearyl fumarate sorbitan laurate - norvir is indicated for use in combination with appropriate antiretroviral agents or as monotherapy if combination therapy is inappropriate, for the treatment of hiv-1 infection in adults and children aged 12 years and older. for persons with advanced hiv disease, the indication for ritonavir is based on the results for one study that showed a reduction in both mortality and aids defining clinical events for patients who received ritonavir. median duration of follow-up in this study was 6 months. the clinical benefit from ritonavir for longer periods of treatment is unknown. for persons with less advanced disease, the indication is based on changes in surrogate markers in controlled trials of up to 16 weeks duration.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - ritonavir -

Israel - English - Ministry of Health

teva israel ltd - fulvestrant - solution for injection - fulvestrant 50 mg/ml - fulvestrant - monotherapyfulvestrant teva is indicated for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:* not previously treated with endocrine therapy,or* with disease relapse on or after adjuvant endocrine therapy, or* with disease progression on endocrine therapy.combination therapyfulvestrant teva is indicated for the treatment of:- hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in men and postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy.- hr- positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

abbvie (pty) ltd - tablet - see ingredients - each tablet contains lopinavir 100,0 mg ritonavir 25,0 mg

Singapore - English - HSA (Health Sciences Authority)

abbvie pte. ltd. - lopinavir; ritonavir - tablet, film coated - 100mg - lopinavir 100mg; ritonavir 25mg

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - lopinavir 100mg; ritonavir 25mg;   - film coated tablet - 100mg/25mg - active: lopinavir 100mg ritonavir 25mg   excipient: colloidal silicon dioxide copovidone opadry white 20c580015 sodium stearyl fumarate sorbitan laurate - lopinavir/ritonavir mylan is indicated for the treatment of hiv-1 infection, in combination with other antiretroviral agents in adults and children aged 2 years and older.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - lopinavir 200mg; ritonavir 50mg;   - film coated tablet - 200mg/50mg - active: lopinavir 200mg ritonavir 50mg   excipient: colloidal silicon dioxide copovidone opadry white 20c580015 sodium stearyl fumarate sorbitan laurate - lopinavir/ritonavir mylan is indicated for the treatment of hiv-1 infection, in combination with other antiretroviral agents in adults and children aged 2 years and older.